Navigation Links
CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators
Date:6/14/2013

SOUTH SAN FRANCISCO, Calif., June 14, 2013 /PRNewswire-iReach/ -- CoMentis, Inc. and Anvyl announced today that the companies have agreed to form Alpharmagen, a joint venture committed to discovering and developing novel modulators of the alpha7 nicotinic receptor.

"CoMentis is extremely pleased to be forming Alpharmagen in partnership with Anvyl" said Terence Kelly,Ph.D, CoMentis' President and CEO. "We believe that alpha7 modulators have the potential to become significant therapeutic agents, and we believe that the portfolio of allosteric modulators and the expertise that Anvyl brings provides a unique 2nd generation approach to the established alpha 7 agonist program that CoMentis has advanced."

"We are pleased to be joining forces with CoMentis in creating Alpharmagen" stated David Putman, Anvyl's Chief Operating Officer. The scientific programs are very complimentary and the teams are well matched in terms of their experience. We believe that we can advance compounds quickly into clinical trials."

About Alpha7 Modulators.

The alpha 7 nicotinic acetylcholine receptor is believed to play a role in cognition and modulators of this receptor in the human brain are reported to have shown promise in Phase 2 clinical trials exploring cognitive disorders associated with schizophrenia and Alzheimer's disease.

About CoMentis:


CoMentis, Inc. has its headquarters in South San Francisco. The company is engaged in the discovery and development of small- molecule drugs to treat Alzheimer's disease.

For more information about CoMentis, please visit the Company's website at www.comentis.com


Contacts:
CoMentis: Terence Kelly, President and Chief Executive Officer (650) 869-7600

About Anvyl

Anvyl LLC is based in Irvine, CA and specializes in the development of drugs for serious neurologic and psychiatric disorders. Anvyl's drug discovery approach uses targeted allosteric modulation of ion channels to correct disease.

For more information about Anvyl, please visit the Company's website at: www.anvylllc.com


Anvyl Contact: David Putman, Chief Operating Officer   
(949) 252-9211

Media Contact: daniel hunt CoMentis, 6502106160, dhunt@comentis.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CoMentis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
3. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Deutsche Bank ... Hotel in Boston, Massachusetts on ... 11:20 a.m. Eastern Time. A live webcast ... Investor Relations website at http://investor.zimmerbiomet.com .  The webcast ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
Breaking Medicine Technology:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... (CDC), rising prescription opioid overdose deaths now claim the lives of 62 Americans ... civil case filings against drug manufacturers, distributors, pharmacies and prescribers by more than ...
(Date:4/24/2017)... ... , ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured in ... the forefront of Gardant since it was founded in 1999. His drive and inquisitive ... more than 40 new senior living communities. With his leadership, Gardant has grown to ...
(Date:4/24/2017)... ... 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 and ... educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd said, ... patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, ...
(Date:4/24/2017)... NY (PRWEB) , ... April 24, 2017 , ... ... 72 countries clearly shows that over the last decade, student well-being has seriously ... all the boxes of formal education, join the Islamic State to turn the ...
(Date:4/24/2017)... ... ... “The Saint with Trin, and Omega Station”: a triple feature offering nonstop ... published author, Chris Jackson. Chris Jackson grew up in Abilene, Texas. He ... District teaching English. He is heavily involved in the youth group of his local ...
Breaking Medicine News(10 mins):